Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.
Schiantarelli J, Benamar M, Park J, Sax HE, Oliveira G, Bosma-Moody A, Campbell KM, Liu D, Johnson DB, Rodig S, Wu CJ, Hodi FS, Ribas A, Van Allen E, Haq R
Cancer Cell. 2025 Feb 10;43(2):308-316.e6. doi: 10.1016/j.ccell.2025.01.009.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 231559 | pMVP-SEC24C | pMVP expression vector for human SEC24C (wild type, closed, resistant to sgSEC24C #1 and #2) (Blasticidin selection marker) |
| 231560 | pMVP-SEC24C-G220C | pMVP expression vector for human SEC24C (G220C mutation, closed, resistant to sgSEC24C #1 and #2) (Blasticidin selection marker) |
| 231561 | pMVP-SEC24C-S107F | pMVP expression vector for human SEC24C (S107F mutation, closesd, resistant to sgSEC24C #1 and #2) (Blasticidin selection marker) |
| 231562 | pLentiCRISPRpuro-sgROSA26 | pLentiCRISPR expression vector for Cas9 and gRNA targeting human ROSA26 locus (Puromycin selection marker) |
| 231563 | pLentiCRISPRpuro-sgSEC24C #1 | pLentiCRISPR expression vector for Cas9 and gRNA targeting human SEC24C (#1) (Puromycin selection marker) |
| 231564 | pLentiCRISPRpuro-sgSEC24C #2 | pLentiCRISPR expression vector for Cas9 and gRNA targeting human SEC24C (#2) (Puromycin selection marker) |
| 231565 | pLentiCRISPRpuro-sgSEC24D | pLentiCRISPR expression vector for Cas9 and gRNA targeting human SEC24D (Puromycin selection marker) |